What the best looks like

Proprietary HT-SPR™ technology

  • 100x the data
  • 10% of the time to answer
  • 1% of the sample requirements of other platforms

Contact Us


  • Market leader in high-throughput antibody characterization
  • Detailed antibody kinetics and epitope binning at the earliest stages of drug discovery
  • Characterization directly from crude material

Learn More


  • All the benefits of LSA plus enhanced data quality for the most demanding applications
  • Rapid kinetics and weak binders such as FcγRs and cytokine panels
  • Small analyte formats such as peptides, PROTAC®s, and protein inhibitors

Learn More

There’s no faster way to discover a therapeutic drug or vaccine.

The fastest, most sensitive, and flexible biosensor platform… ever.

Eli Lilly developed bamlanivimab, the world’s First COVID-19 therapeutic, on the Carterra LSA platform in a 90-day sprint.

Learn More

This is what high throughput kinetics looks like.

You can’t generate this much data any other way.  And if you’re wondering:

  • Screening and characterization in the same step — 384 full kinetic profiles in a day
  • 50x faster — Data quality is the same as your low throughput gold standard instrument
  • 1% of the sample you’ve been pouring into your current biosensor

Learn More

This is what a high-res epitope binning looks like.

If you’re not binning or just binning 10s of antibodies at a time, you’re not finding out much about your epitope.

  • Bin up to 384 × 384 antibodies (that’s about 150,000 sensorgrams if you’re wondering)
  • Discover the Mechanism of Action quickly and reduce failures in development and the clinic
  • Obtain Intellectual Property rights and lock down features that differentiate your antibody from your competitors

Learn More

Want to Learn More?

Speak to a Carterra Scientist

News & Events

Curia and Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific Northwest



Curia and Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific Northwest

Read More


Check out the Science Webinar: Advances in HT-SPR, scBCR-seq and RNA-seq

View the Webinar


Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern